TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Average daily oral retention of triclosan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total triclosan plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in fat-free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in serum LDL-cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximum duration of abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic bleeding from the colpotomy wound for more than 7 days
Endpoint domain: Adverse events/effects
Primary endpoint: Fatigue score increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of differentially expressed genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hyperfiltration prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum and urine NO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gross manual dexterity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper-limb ability during functional tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient social participation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Proportion of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Platelet response (Aspirin Response Unit)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean serum testosterone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Likelihood of menses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 42-day cure rates
Endpoint domain: Mortality/survival
Primary endpoint: Mean OSCE score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on multiple-choice exam's therapeutics content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative rate of ischemic cerebrovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Duration of uterine contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interval of uterine contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma low-density lipoprotein cholesterol (LDL-C) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Interleukin-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of facet joint tropism (FT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking relapse risk
Endpoint domain: Adverse events/effects
Primary endpoint: Weight gain after smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: requirement for emergency operation
Endpoint domain: Adverse events/effects
Primary endpoint: clinical rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of injections required in the first year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No clinical impairment at the end of observation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke or death because of uBAVM or intervention
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in acute pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in drinking outcome 12 months later
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in BSS from baseline to day seven
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alive and no decline in ambulation, transfers, or residence
Endpoint domain: Mortality/survival
Primary endpoint: internal rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: external rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: occurrence of any adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Cognition (NCS T-score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functioning (PSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of sarcoidosis
Endpoint domain: Adverse events/effects
Primary endpoint: Mean total POSAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Scar color
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in acidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total MiniAQLQ score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ACQ score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Decrease in rescue bronchodilator use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faecal frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: diuretic and natriuretic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in anxiety scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial glycaemic excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: insulin resistance or calculated insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Post-ERC pancreatitis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Verified abstinence at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Utilization of cessation medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain associated with early medical abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical success of the primary joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean lesion remineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual rate of stroke
Endpoint domain: Mortality/survival
Primary endpoint: Risk reduction of stroke with warfarin
Endpoint domain: Mortality/survival
Primary endpoint: Annual rate of major hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Knee dynamic valgus angle improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean postoperative Lysholm scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean postoperative Kujala scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of good or excellent outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: incremental cost per year of life gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Follow-up BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to 100% twitch depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 50% twitch depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bleeding recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: SpO2 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving plasma urate <6 mg/dl for 80% of the study period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of psychodynamic therapy vs. CBT in GAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum F25D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum T25D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intercourse penetration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-intercourse penetration improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear of coitus reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effectiveness of audiovisual distraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: return of spontaneous circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: carotid blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients completing intended cycles at relative dose intensity >= 85%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean fasting plasma glucose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall healing after 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence at 2-year revision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean resting pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posttherapy clinical resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eradication of pretreatment bacterial isolates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PD-associated gait disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-6 concentration postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CRP levels postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absence of recurrence of neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regression of plus disease and peripheral retinal vessels development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normalization of oxidative stress markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average test time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average MD (mean deviation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Threshold measurements outside normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 20-year cumulative incidence of IBTR
Endpoint domain: Mortality/survival
Primary endpoint: prevent premature death
Endpoint domain: Mortality/survival
Primary endpoint: Temptation to smoke
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in mean carotid intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inflammatory side effects (erythema, edema, folliculitis)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in AHA units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active supination improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Professionalism and patient-doctor communication ratings
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time for first independent performance of gastric-tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rotator cuff output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Successful discontinuation of PPIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of GERD patients off PPIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of dental plaque measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint space width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Days of apnea attacks within 7 days after birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of inflammatory and noninflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adverse events related to skin irritation
Endpoint domain: Adverse events/effects
Primary endpoint: 7 day alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: binge drinking episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regression in the size of the lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete clearance of the lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first major coronary events
Endpoint domain: Mortality/survival
Primary endpoint: any cardiovascular event
Endpoint domain: Mortality/survival
Primary endpoint: Lingual fractures originating from the inferior border cut
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bad splits
Endpoint domain: Adverse events/effects
Primary endpoint: Need for manipulation of IAN
Endpoint domain: Adverse events/effects
Primary endpoint: Time to pass faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma ascorbic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extra 1 year of survival time
Endpoint domain: Mortality/survival
Primary endpoint: extra 5% in survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Average daily dietary vitamin D intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average daily dietary calcium intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma lanthanum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total bone lanthanum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean levels of total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hypertension control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median myocardial salvage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early mortality risk
Endpoint domain: Mortality/survival
Primary endpoint: Time to red cell transfusion independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral Blood Volume (CBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-24 values of tacrolimus absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: alteration of cervical cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of any pathological result in cardiotocography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of fetal bradycardia
Endpoint domain: Adverse events/effects
Primary endpoint: Performance on delayed prose recall task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma tryptophan levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Central epithelial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Digit Symbol test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Repeat revascularization events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Major adverse events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Pain intensity at rest score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulty passing urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of overweight/obese children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-reported improvement in symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum levels of enterolactone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of alpha-linolenic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean graft number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory dyspnea, hoarseness, barking cough and stridor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of seizure freedom at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-6 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TNF-α expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage neointimal hyperplasia (%NIH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: degree of strut coverage/apposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical cure with or without sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cured with no sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizures during treatment
Endpoint domain: Adverse events/effects
Primary endpoint: aortic strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decline in forced expiratory volume in 1s (FEV(1)) or forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of ovarian cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kilocalorie intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feelings of improved health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: psycho-functional recovery scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delirium severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attention switching functional signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum levels of DKK1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of being diagnosed with metastatic prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Dentists' compliance with the SIGN guideline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced angina episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced nitroglycerin consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced ischemia by electromechanical mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MATRICS Consensus Cognitive Battery composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: egg reduction rate for Ascaris lumbricoides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: egg reduction rate for hookworm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: egg reduction rate for Trichuris trichiura
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Impaired glucose tolerance (IGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes